PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT05313165
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 100 participants
- Sponsor
- LimFlow, Inc.
- Registry
-
NCT05313165
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05313165. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-22 (actual); primary completion 2027-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
- Condition
- Critical Limb Ischemia
- Condition
- Chronic Limb-Threatening Ischemia
- Condition
- Peripheral Arterial Disease
- Intervention (Device)
- LimFlow Stent Graft System
- Lead sponsor
- LimFlow, Inc.
Record details
- Record id
cardio:ct-nct05313165- Content hash
1c51a3a81824e99df8f4d83d2d88d9f9b3fe5c3ab7324fed0b5b8b05f543c842